Literature DB >> 23302914

Anthrax drug first antibacterial mAb to win approval.

Jeffrey L Fox.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23302914     DOI： 10.1038/nbt0113-8

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  GSK buys partner Human Genome Sciences.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908
  1 in total
  10 in total

Review 1.  Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Authors:  Jacqueline Sharon; Michael J Rynkiewicz; Zhaohua Lu; Chiou-Ying Yang
Journal:  Immunology       Date:  2014-05       Impact factor: 7.397

2.  Anti-infective monoclonals step in where antimicrobials fail.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2013-11       Impact factor: 54.908

3.  Biotech drugs too little, too late for Ebola outbreak.

Authors:  Stephen Strauss
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908

4.  What's fueling the biotech engine-2012 to 2013.

Authors:  Rob Saurabh Aggarwal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

Review 5.  Designing inhibitors of anthrax toxin.

Authors:  Ekaterina M Nestorovich; Sergey M Bezrukov
Journal:  Expert Opin Drug Discov       Date:  2014-01-22       Impact factor: 6.098

6.  Detection and measurement of staphylococcal enterotoxin-like K (SEl-K) secretion by Staphylococcus aureus clinical isolates.

Authors:  Jorge L Aguilar; Avanish K Varshney; Xiaobo Wang; Lindsay Stanford; Matthew Scharff; Bettina C Fries
Journal:  J Clin Microbiol       Date:  2014-05-07       Impact factor: 5.948

7.  Mapping the epitopes of a neutralizing antibody fragment directed against the lethal factor of Bacillus anthracis and cross-reacting with the homologous edema factor.

Authors:  Philippe Thullier; Arnaud Avril; Jacques Mathieu; Christian K Behrens; Jean-Luc Pellequer; Thibaut Pelat
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

8.  Multivalent dendritic molecules as broad spectrum bacteria agglutination agents.

Authors:  Shuzhang Xiao; Lica Abu-Esba; Serhan Turkyilmaz; Alexander G White; Bradley D Smith
Journal:  Theranostics       Date:  2013-08-10       Impact factor: 11.556

Review 9.  Monoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin Drugs.

Authors:  Eran Diamant; Amram Torgeman; Eyal Ozeri; Ran Zichel
Journal:  Toxins (Basel)       Date:  2015-05-29       Impact factor: 4.546

10.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.